Celularity Inc (CELU)vsModerna Inc (MRNA)
CELU
Celularity Inc
$1.31
-7.75%
HEALTHCARE · Cap: $38.21M
MRNA
Moderna Inc
$226.30
+4.65%
HEALTHCARE · Cap: $75.86B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 8292% more annual revenue ($2.23B vs $26.55M). CELU leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).
CELU
Avoid18
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+71.8%
Fair Value
$4.36
Current Price
$1.31
$3.05 discount
Margin of Safety
+69.9%
Fair Value
$134.58
Current Price
$226.30
$91.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -6367.0% — below average capital efficiency
Trading at 13.4x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CELU
The strongest argument for CELU centers on Debt/Equity.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Profit Margin, Piotroski F-Score.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CELU profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.11 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
CELU generates stronger free cash flow (1M), providing more financial flexibility.
Bottom Line
MRNA scores higher overall (21/100 vs 18/100). CELU offers better value entry with a 71.8% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is a pioneering biotechnology company focused on regenerative medicine through its innovative cellular products derived from the placenta. The company is advancing a promising pipeline of allogeneic immunotherapies aimed at enhancing treatment outcomes for cancer patients and those with severe medical conditions, while reducing associated complications. With a strong leadership team and strategic partnerships, Celularity is positioned to become a significant force in the dynamic advanced therapeutics sector, addressing critical unmet medical needs and driving advancements in patient care.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?